Search

Uric acid

At present (August 2013), there is no approved formulation or indication for uric acid.

CX-052075

approved COVID-19 mRNA vaccines, including the original Moderna COVID-19 vaccine ([elasomeran]), CX-052075 encodes only the immunodominant regions (NTD and RBD) of the SARS-CoV-2 spike protein, allowing for … [L53413,A274083] mNEXSPIKE was approved by the US FDA in June 2025 for use in patients who have been previously vaccinated with any COVID-19 vaccine and who are at a higher risk of severe outcomes from

Flupentixol

It is approved for use in Canada and other countries around the world, but not in the US. … It is used for the management of chronic schizophrenia in patients whose main manifestations do not include excitement, agitation or hyperactivity.

Fludrocortisone

Fludrocortisone is a synthetic mineralocorticoid used in conjunction with hydrocortisone to replace missing endogenous corticosteroids in patients with adrenal insufficiency. It is functionally similar to aldosterone, the body's primary ...

Rucaparib

an androgen receptor–directed therapy, confirming clinical benefit for an indication that previously had accelerated approval. … On December 17, 2025, the FDA granted regular approval to rucaparib for adults with a deleterious BRCA mutation–associated metastatic castration-resistant prostate cancer (mCRPC) previously treated with

Tofersen

[L46133] In June of 2024, it was additionally approved by the EMA for the same indication. … [A259028,A259033] Tofersen was granted accelerated approval from the FDA on April 25, 2023, as the first treatment for adults with ALS caused by SOD1 mutation.

Binodenoson

Binodenoson is a pharmacologic stress agent specific to the only adenosine receptor necessary for increased cardiac blood flow, the A_2A receptor.

Synthetic camphor

Milsaperidone

[L56056] On February 20, 2026, milsaperidone was approved by the FDA for the treatment of Bipolar I Disorder and schizophrenia.[L56059]

Tafamidis

Tafamidis and tafamidis meglumine (FX-1006A) are benzoxazole derivatives developed by FoldRX. Tafamidis is structurally similar to diflusinal. Tafamidis was granted an EMA market authorisation on 16 November 2011 and FDA approval on 3 Ma...